Intrathoracic esophagojejunostomy using OrVil™ for gastric adenocarcinoma involving the esophagus

Table 1 Patients’ clinical background

Case	Age (yr)	Sex	Tumor location	Siewert classification	C-length (mm)	C-stage	Co-morbidity	Neoadjuvant chemotherapy
1	73	M	EU	Type I	30	T3(SS)N0M0	DM	N
2	52	M	UME	Others	14	T3(SS)N1M0	DM	N
3	80	M	EU	Type II	21	T3(SS)N1M0	CI	N
4	67	M	UE	Type II	10	T1b(SM)N0M0	DM, COPD	N
5	55	M	UE	Type III	12	T3(SS)N2M0	COPD	S-1 + CDDP

C-stage: Clinical stage; C-length: Clinical length of the esophageal involvement according to preoperative fluoroscopy; DM: Diabetes mellitus; CI: Cerebral infarction; COPD: Chronic obstructive Pulmonary disease; N: Not performed; M: Male.

Table 2 Surgical outcomes

Case	Surgical	Lymph-	Residual	Operation time	Blood loss	Start of foods	Hospital stay	E-length	P-length
	procedures	adenectomy	tumor	(min)	(mL)	(d)	(d)	(mm)	(mm)
1	Total GR, RY	D2	R0	367	838	10	20	55	48
2	Total GR, RY	D2	R0	314	270	10	16	40	14
3	Total GR, RY	D2	R0	210	210	7	15	52	22
4	Proximal GR, JI	D1+	R0	314	100	7	18	36	6
5	Total GR, RY	D2	R0	277	140	6	15	35	10

Total GR: Total gastrectomy; Proximal GR: Proximal gastrectomy; RY: Roux-en Y reconstruction; JI: Jejunal interposition; R0: No residual tumor; E-length: Length of resected esophagus; P-length: Pathological length of esophageal involvement.